全球siRNA化學品、連接劑和試劑市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球siRNA化學連接劑和試劑市場規模預計將從2025年的9.5191億美元成長至2034年的31.4974億美元，2026年至2034年的複合年成長率（CAGR）為14.22%。該市場正經歷快速成長，這主要得益於小干擾RNA（siRNA）技術在基因靜默研究、精準醫療和先進療法開發中日益重要的地位。 siRNA合成中使用的化學品、連接劑和試劑在提高分子穩定性、遞送效率、標靶特異性和治療效果方面發揮著至關重要的作用。生物技術、基因組學和藥物研發領域投資的增加正在顯著加速全球市場的擴張。

RNA療法臨床開發的進展，以及對遺傳疾病、癌症治療、感染疾病和罕見疾病研究的不斷深入，正在推動對高品質siRNA生產原料的需求。結合化學、核苷酸修飾、脂質遞送系統和合成技術的持續創新，正在提升產品性能並提高商業性化規模。製藥公司、生物技術公司和研究機構之間日益密切的合作，進一步促進了產業的成長。

隨著RNA療法、個人化醫療和基因編輯技術在全球的持續發展，預計該市場將保持顯著成長。化學合成、遞送平台、自動化生產和監管合規的不斷改進將推動商業性化應用。對精準醫療投入的增加、臨床試驗的擴展以及RNA藥物商業化的進展，將繼續創造巨大的長期市場機會。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球siRNA化學品、連接劑和試劑市場：按類型分類

• 市場分析、洞察與預測
• 用於siRNA合成的化學品
• 化學改質劑
• 連接器
• 結合試劑
• 遞送相關試劑
• 其他

第5章：全球siRNA化學品、連接劑和試劑市場：按應用分類

• 市場分析、洞察與預測
• 藥物研發
• 調查與探勘
• 藥物傳輸平台的開發
• 其他

第6章 全球siRNA化學品、連接劑和試劑市場：依最終用途分類

• 市場分析、洞察與預測
• 製藥和生物技術公司
• CMO／CDMO
• 學術研究機構
• 其他

第7章 全球siRNA化學品、連接劑和試劑市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Thermo Fisher Scientific
  • Merck KGaA
  • Agilent Technologies
  • Danaher Corporation
  • Bachem
  • LGC Biosearch Technologies
  • WuXi AppTec
  • Nitto Denko Avecia
  • Bio-Synthesis
  • Maravai LifeSciences
  • Glen Research
  • ChemGenes Corporation
  • Alnylam Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Silence Therapeutics
  • Ionis Pharmaceuticals
  • Arbutus Biopharma
  • Benitec Biopharma
  • Marina Biotech
  • Quark Pharmaceuticals
  • RXi Pharmaceuticals
  • Sirnaomics
  • Genevant Sciences
  • BioNTech
  • Moderna
  • Pfizer Inc
  • Sanofi SA
  • Roche Holding AG
  • Merck And Co

The global siRNA chemical linkers and reagents market size is expected to reach USD 3149.74 Million in 2034 from USD 951.91 Million in 2025, growing at a CAGR of 14.22 during 2026-2034.This market is witnessing rapid growth as small interfering RNA technologies continue gaining importance in gene silencing research, precision medicine, and advanced therapeutic development. Chemicals, linkers, and reagents used in siRNA synthesis play a critical role in improving molecular stability, delivery efficiency, target specificity, and therapeutic performance. Rising investments in biotechnology, genomics, and pharmaceutical research are significantly accelerating market expansion worldwide.

Growing clinical development of RNA-based therapeutics, increasing research into genetic disorders, cancer treatments, infectious diseases, and rare diseases are driving demand for high-quality siRNA manufacturing materials. Continuous innovation in conjugation chemistry, nucleotide modification, lipid delivery systems, and synthesis technologies is enhancing product performance while improving commercial scalability. Expanding collaborations between pharmaceutical companies, biotechnology firms, and research institutions are further supporting industry growth.

The market is expected to maintain exceptional growth as RNA therapeutics, personalized medicine, and gene-editing technologies continue advancing globally. Continuous improvements in chemical synthesis, delivery platforms, automated manufacturing, and regulatory compliance will strengthen commercial adoption. Increasing investments in precision healthcare, expanding clinical trials, and growing commercialization of RNA-based medicines will continue creating substantial long-term market opportunities.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• siRNA Synthesis Chemicals
• Chemical Modifiers
• Linkers
• Conjugation Reagents
• Delivery-Related Reagents
• Others

By Application

• Therapeutics Development
• Research & Discovery
• Drug Delivery Platform Development
• Others

By End-use

• Pharmaceutical & Biotechnology Companies
• CMOs / CDMOs
• Academic & Research Institutes
• Others

COMPANIES PROFILED

• Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, Danaher Corporation, Bachem, LGC Biosearch Technologies, WuXi AppTec, Nitto Denko Avecia, Bio-Synthesis, Maravai LifeSciences, Glen Research, ChemGenes Corporation, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Ionis Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, Marina Biotech, Quark Pharmaceuticals, RXi Pharmaceuticals, Sirnaomics, Genevant Sciences, BioNTech, Moderna, Pfizer Inc., Sanofi S.A., Roche Holding AG, Merck and Co.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SIRNA CHEMICAL, LINKERS AND REAGENTS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. siRNA Synthesis Chemicals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Chemical Modifiers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Linkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Conjugation Reagents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Delivery-Related Reagents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SIRNA CHEMICAL, LINKERS AND REAGENTS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Therapeutics Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Research & Discovery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Drug Delivery Platform Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SIRNA CHEMICAL, LINKERS AND REAGENTS MARKET: BY END-USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. CMOs / CDMOs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SIRNA CHEMICAL, LINKERS AND REAGENTS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By End-use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SIRNA CHEMICAL, LINKERS AND REAGENTS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Thermo Fisher Scientific
  • 9.2.2 Merck KGaA
  • 9.2.3 Agilent Technologies
  • 9.2.4 Danaher Corporation
  • 9.2.5 Bachem
  • 9.2.6 LGC Biosearch Technologies
  • 9.2.7 WuXi AppTec
  • 9.2.8 Nitto Denko Avecia
  • 9.2.9 Bio-Synthesis
  • 9.2.10 Maravai LifeSciences
  • 9.2.11 Glen Research
  • 9.2.12 ChemGenes Corporation
  • 9.2.13 Alnylam Pharmaceuticals
  • 9.2.14 Arrowhead Pharmaceuticals
  • 9.2.15 Silence Therapeutics
  • 9.2.16 Ionis Pharmaceuticals
  • 9.2.17 Arbutus Biopharma
  • 9.2.18 Benitec Biopharma
  • 9.2.19 Marina Biotech
  • 9.2.20 Quark Pharmaceuticals
  • 9.2.21 RXi Pharmaceuticals
  • 9.2.22 Sirnaomics
  • 9.2.23 Genevant Sciences
  • 9.2.24 BioNTech
  • 9.2.25 Moderna
  • 9.2.26 Pfizer Inc
  • 9.2.27 Sanofi S.A
  • 9.2.28 Roche Holding AG
  • 9.2.29 Merck And Co